Drugs / D-glucose
D-glucose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04945499 | Jun 2019 → Jun 2022 | — | Zhujiang Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05724134 Background | Aug 2023 → Sep 2025 | NAFLD1, hyperinsulinism, obesity disorder, prediabetes syndrome | Columbia University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | d-glucose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04945499 ↗ |
| Known as | 20% D-glucose (aq) | “20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.” NCT05724134 ↗ |
| Known as | D20W | “20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.” NCT05724134 ↗ |
| Modality | Diagnostic / imaging agent | “using d-glucose as an contrast agent on CEST MR Imaging” NCT04945499 ↗ |
| Route | Intravenous | “intravenous bolus of D-glucose” NCT04945499 ↗ |